Cytokine Kinetics in Febrile Neutropenic Children: Insights on the Usefulness as Sepsis Biomarkers, Influence of Filgrastim, and Behavior of the IL-23/IL-17 Pathway
Table 2
General data (N, %). IQR: interquartile range.
N
35
Age (years, median, IQR)
5.84 (3.7–10.3)
Male
10 (28.6%)
Received antibiotics
35 (100%)
Diagnoses
Acute lymphocytic leukemia
6 (17.1%)
Acute myelogenous leukemia
3 (8.6%)
Non-Hodgkin’s lymphoma
6 (17.1%)
Wilms’ tumor
4 (11.4%)
Primitive neuroectodermal tumor (PNET)
2 (5.7%)
Retinoblastoma
2 (5.7%)
Ewing’s sarcoma
2 (5.7%)
Chronic myeloid leukemia
1 (2.9%)
Other solid tumors
9 (25.7%)
Received filgrastim
19 (54.2%)
Days receiving filgrastim before day 1 of the study (mean, range)
